Syros Pharmaceuticals, Inc.
NASDAQ:SYRS
Overview | Financials
Company Name | Syros Pharmaceuticals, Inc. |
Symbol | SYRS |
Currency | USD |
Price | 0.209 |
Market Cap | 5,607,993 |
Dividend Yield | 0% |
52-week-range | 0.183 - 8.17 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Nancy A. Simonian M.D. |
Website | https://www.syros.com |
An error occurred while fetching data.
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD